Udies. Informative data, currently in clinical trials, lapatinib. Lapatinib Cilomilast SB-207499 has been created specifically for the treatment of HER2 overexpression and numerous clinical trials on the efficacy and correlative scientific studies and are designed to make the activity of t T of Agent to determine in cancer patients overexpress HER2. Justified study of efficiency and better phase II to the date, which overexpresses a response rate of 8% in 4 patients with HER2 breast cancer show. Two other studies are under way, but preferred unbest reported response rates Heren h in size Order of a 24 30%. A number of other phase II trials are underway to test the effectiveness of the other experimental ITS TKI in patients with HER2 overrexpressing and there will be many more new data in the coming years.
The data we have evidence of claims against black t Krankheitsaktivit clinical disease seen. Zus tzlich Moasser studies by numerous clinical studies hearts tee rated 9 Oncogene. Author manuscript 6th, April 2011 PMC. To determine whether the addition of cytotoxic chemotherapy for hormone therapy or trastuzumab TKI new combinations with increased hter clinical activity t MK-2866 t hter and Verl EXTENSIONS w during the lifetime of the patient produces. K these studies Can better Behandlungsm k command guidance for control patients, but they are not a direct test of the HER2 oncogene hypothesis and a detailed discussion of these studies is beyond the scope of this review. Evidence that HER2 TKI advance patient inhibit HER2 oncogene hypothesis would focus the vast majority of tumors HER2 H Chster no treatments that respond to suppress the function of the HER2 kinase.
Correlation studies of tumor patients under treatment are important in order to understand if the function of the HER2 signaling and was effectively eliminated by these treatments. These correlational studies require intervention basic research to patient consent tumor biopsies just before and w During treatment with U and these studies are difficult to achieve a variety of practical and ethical reasons. At least two groups able to produce clinical data for the patient to TKI SES. In a Phase I clinical trial with lapatinib tumor biopsies were obtained before and w W During the treatment, the tumor-suppressor signaling EGFR/HER2 by immunohistochemical staining F Determine F.
This study showed mixed results with varying degrees of goals repression, in part because it is a phase I dose-escalation study in patients with various types of cancer, including cancer not known to the normal Ngig is dependent ngig be HER2 and starting doses of the target are probably less effective remedy. However, the data show a decrease in the phosphorylation of EGFR and HER2 in most patients, and a reduction of the MAP kinase signaling. A reduction of Akt signaling is less obvious in this case. In a phase II study of gefitinib in patients with breast cancer, skin biopsies and tumor biopsies in many patients before and w During treatment w immunohistochemical analysis for the removal of the target is obtained. This study has demonstrated an effective suppression of the phosphorylation of EGFR and MAPK in sk